Alpha-Emitting Prostate Cancer Therapy 212Pb-ADVC001 Well Tolerated in First-in-Human Trial
In the first-in-human TheraPb phase 1 trial, the alpha-emitting radiopharmaceutical 212Pb-ADVC001 was well tolerated at doses of 60–200 MBq with ...
Tag: PSA response
POPULAR NEWS
-
Nurturing early years programmes may curb mental health problems in children facing poverty
-
Dual smoking and drinking affects one in 13 Malawian men, survey finds
-
Ethiopian Emergency Clinicians Show Strong AI Attitudes but Skill Gaps Persist
-
Perioperative apalutamide cuts metastasis and death risk in high-risk prostate cancer substudy